Tabriz University of Medical Sciences Advanced Pharmaceutical Bulletin 2228-5881 12 3 2022 05 21 CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy 476 489 10.34172/apb.2022.051 EN Behrouz Shademan https://orcid.org/0000-0003-2663-723X Vahidreza Karamad Alireza Nourazarian Cigir Biray Avcı https://orcid.org/0000-0002-2748-3124 REVIEW 10.34172/apb.2022.051 2021 02 16 2021 08 17 Immunotherapy has become a prominent strategy for the treatment of cancer. A method that improves the immune system’s ability to attack a tumor (Enhances antigen binding). Targeted killing of malignant cells by adoptive transfer of chimeric antigen receptor (CAR) T cells is a promising immunotherapy technique in the treatment of cancers. For this purpose, the patient’s immune cells, with genetic engineering aid, are loaded with chimeric receptors that have particular antigen binding and activate cytotoxic T lymphocytes. That increases the effectiveness of immune cells and destroying cancer cells. This review discusses the basic structure and function of CAR-T cells and how antigenic targets are identified to treat different cancers and address the disadvantages of this treatment for cancer.